|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-4.03/-0.25
|
企業價值
494.12M
|
資產負債 |
每股賬面淨值
0.41
|
現金流量 |
現金流量率
--
|
損益表 |
收益
687.20M
|
每股收益
0.48
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/16 23:44 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, whichis the development, production, marketing and sale of biopharmaceutical products. |